Small Cell Lung Carcinoma

Oncology
12
Pipeline Programs
8
Companies
36
Clinical Trials
7 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
3
0
3
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
360%
Small Molecule
240%
+ 5 programs with unclassified modality

On Market (3)

Approved therapies currently available

AstraZeneca
IMFINZIApproved
durvalumab
AstraZeneca
Programmed Death Ligand-1 Blocker [EPC]injection2017
Novartis
TAFINLARApproved
dabrafenib
Novartis
oral2013
Roche
TECENTRIQApproved
atezolizumab
Roche
Programmed Death Receptor-1 Blocking Antibody [EPC]injection2016

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
3 programs
1
1
1
LBH581Phase 21 trial
225Ac-ETN029Phase 11 trial
TAFINLAR(Dabrafenib)N/ASmall Molecule5 trials
Active Trials
NCT04489433No Longer Available
NCT04507919No Longer Available
NCT05868629Recruiting40Est. Mar 2028
+4 more trials
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
1
AtezolizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT04028050Completed155Est. Jul 2023
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
1
DurvalumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT06992609Recruiting70Est. Jun 2029
Pfizer
PfizerNEW YORK, NY
1 program
1
Etoposide + cisplatinPhase 31 trial
Active Trials
NCT00143455Completed485Est. Dec 2008
Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
AmuvatinibPhase 2Small Molecule1 trial
Active Trials
NCT01357395CompletedEst. May 2012
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BI 764532, dose 1Phase 21 trial
Active Trials
NCT05882058Recruiting174Est. Feb 2028
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
LY2940680Phase 1/21 trial
Active Trials
NCT01722292Terminated26Est. Feb 2015
DS
Daiichi SankyoChina - Shanghai
1 program
1
coformulation pembrolizumab/quavonlimabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT04938817Recruiting110Est. Dec 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
NovartisDabrafenib
NovartisDabrafenib
AstraZenecaDurvalumab
RocheAtezolizumab
NovartisDabrafenib
PfizerEtoposide + cisplatin
Boehringer IngelheimBI 764532, dose 1
NovartisDabrafenib
NovartisDabrafenib
NovartisDabrafenib
NovartisDabrafenib
NovartisDabrafenib
NovartisDabrafenib
NovartisDabrafenib
NovartisDabrafenib

Showing 15 of 34 trials with date data

Clinical Trials (36)

Total enrollment: 4,167 patients across 36 trials

NCT03975829NovartisDabrafenib

Pediatric Long-Term Follow-up and Rollover Study

Start: Nov 2019Est. completion: Nov 2026163 patients
Phase 4Active Not Recruiting
NCT03340506NovartisDabrafenib

Dabrafenib and/or Trametinib Rollover Study

Start: Dec 2017Est. completion: Dec 2030100 patients
Phase 4Recruiting
NCT06992609AstraZenecaDurvalumab

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

Start: Sep 2025Est. completion: Jun 202970 patients
Phase 3Recruiting
NCT04028050RocheAtezolizumab

A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Start: Aug 2019Est. completion: Jul 2023155 patients
Phase 3Completed
NCT01597908NovartisDabrafenib

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Start: Jun 2012Est. completion: Apr 2019704 patients
Phase 3Completed
NCT00143455PfizerEtoposide + cisplatin

Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer

Start: Jun 2002Est. completion: Dec 2008485 patients
Phase 3Completed
NCT05882058Boehringer IngelheimBI 764532, dose 1

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Start: Oct 2023Est. completion: Feb 2028174 patients
Phase 2Recruiting
NCT06079333NovartisDabrafenib

NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

Start: Jan 2023Est. completion: Jan 202820 patients
Phase 2Recruiting
NCT04452877NovartisDabrafenib

A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

Start: Aug 2020Est. completion: Nov 202440 patients
Phase 2Completed
NCT02672358NovartisDabrafenib

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Start: Sep 2018Est. completion: Dec 20200
Phase 2Withdrawn
NCT02684058NovartisDabrafenib

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Start: Dec 2017Est. completion: Apr 2023151 patients
Phase 2Completed
NCT02367859NovartisDabrafenib

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Start: Jul 2017Est. completion: Jun 20191 patients
Phase 2Completed
NCT02083354NovartisDabrafenib

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Start: Mar 2014Est. completion: Apr 202177 patients
Phase 2Completed
NCT02034110NovartisDabrafenib

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Start: Mar 2014Est. completion: Dec 2021206 patients
Phase 2Completed
NCT01682213NovartisDabrafenib

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Start: Sep 2012Est. completion: May 201923 patients
Phase 2Completed
NCT01357395Astex PharmaceuticalsAmuvatinib

A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer

Start: May 2011Est. completion: May 2012
Phase 2Completed
NCT01222936NovartisLBH581

LBH Phase II in Small Cell Lung Cancer (SCLC)

Start: May 2008Est. completion: Aug 201021 patients
Phase 2Completed
NCT04938817Daiichi Sankyocoformulation pembrolizumab/quavonlimab

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Start: Aug 2021Est. completion: Dec 2029110 patients
Phase 1/2Recruiting
NCT03455764NovartisDabrafenib

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

Start: Sep 2018Est. completion: Sep 20236 patients
Phase 1/2Completed
NCT02124772NovartisDabrafenib

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Start: Jan 2015Est. completion: Dec 2020139 patients
Phase 1/2Completed
NCT01902173NovartisDabrafenib

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Start: Oct 2013Est. completion: Dec 202327 patients
Phase 1/2Completed
NCT01677741NovartisDabrafenib

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Start: May 2013Est. completion: Dec 202085 patients
Phase 1/2Completed
NCT01722292Eli Lilly and CompanyLY2940680

A Study of LY2940680 in Small Cell Lung Cancer

Start: Jan 2013Est. completion: Feb 201526 patients
Phase 1/2Terminated
NCT01750918NovartisDabrafenib

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

Start: Dec 2012Est. completion: Jun 2020166 patients
Phase 1/2Completed
NCT07006727Novartis225Ac-ETN029

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Start: Oct 2025Est. completion: Jun 2031116 patients
Phase 1Recruiting
NCT03091257NovartisDabrafenib

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Start: Jun 2017Est. completion: Sep 202630 patients
Phase 1Active Not Recruiting
NCT02873650NovartisDabrafenib

Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment

Start: Dec 2016Est. completion: Apr 20195 patients
Phase 1Terminated
NCT02852239NovartisDabrafenib

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

Start: Dec 2016Est. completion: Sep 201922 patients
Phase 1Completed
NCT04507919NovartisDabrafenib

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

N/ANo Longer Available
NCT04489433NovartisDabrafenib

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

N/ANo Longer Available
NCT05868629NovartisDabrafenib

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Start: Feb 2024Est. completion: Mar 202840 patients
N/ARecruiting
NCT06557291NovartisDabrafenib

Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma

Start: Oct 2022Est. completion: Nov 202338 patients
N/ACompleted
NCT06337617NovartisDabrafenib

A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

Start: May 2022Est. completion: Jun 202390 patients
N/ACompleted
NCT05171374NovartisDabrafenib

pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE

Start: Sep 2021Est. completion: Sep 2024500 patients
N/AUnknown
NCT05806268NovartisDabrafenib

Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients

Start: Jul 2021Est. completion: Mar 2022214 patients
N/ACompleted
NCT04775095NovartisDabrafenib

BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation

Start: Mar 2021Est. completion: Dec 2021163 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
7 actively recruiting trials targeting 4,167 patients
8 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)